Peptide Atlas · Peptide

Thymopentin (TP5)

In a double-blind trial in 100 patients with moderate to severe atopic dermatitis, six weeks of daily subcutaneous thymopentin reduced clinical severity, itching and redness more than placebo.

emerging

provisional
PubChem 451417
2 citations
0 discussions
0 followers
RKDVY
TP5
Timunox
thymopoietin (32-36)

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

created page created as 'Thymopentin (TP5)' with aliases TP5, thymopoietin (32-36), RKDVY, Timunox · 2026-09-27 12:04 · somebody
kind set kind set to peptide: palette r2 · 2026-09-27 12:04 · somebody
fact added identity: PubChem CID 451417: Thymopentin, C30H49N9O9, 679.8 g/mol. · 2026-09-27 12:04 · somebody
fact added identity: CAS registry number 69558-55-0. · 2026-09-27 12:04 · somebody
fact added identity: IUPAC name: (3S)-3-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-4-[[(2S)-1 · 2026-09-27 12:04 · somebody
fact added summary: In a double-blind trial in 100 patients with moderate to severe atopic dermatitis, six weeks of daily subcutaneous thymo · 2026-09-27 12:04 · somebody
fact added summary: In hemodialysis patients who had not responded to hepatitis B vaccination, adding thymopentin to revaccination raised th · 2026-09-27 12:04 · somebody
citation added pmid 2185294 cited as emerging: Thymopentin reduced atopic dermatitis severity versus placebo (RCT, n=100) · 2026-09-27 12:04 · somebody
citation added pmid 3065661 cited as emerging: Thymopentin improved hepatitis B vaccine response in hemodialysis non-responders (RCT, n=40) · 2026-09-27 12:04 · somebody

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.